13-May-2024
Amphastar Pharmaceuticals to Present at the Bank of America Securities Health Care Conference
ACCESSWIRE (Thu, 9-May 4:11 PM ET)
Analysts Offer Insights on Healthcare Companies: Amphastar Pharmaceuticals (AMPH) and Erasca (ERAS)
TipRanks (Thu, 9-May 8:50 AM ET)
Amphastar Pharmaceuticals (AMPH) Receives a Buy from Piper Sandler
TipRanks (Thu, 9-May 6:53 AM ET)
Amphastar Pharmaceuticals: Hold Rating Justified Amidst Growth Prospects and Pipeline Potential
TipRanks (Thu, 9-May 6:47 AM ET)
TipRanks (Thu, 9-May 6:11 AM ET)
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024
ACCESSWIRE (Wed, 8-May 4:08 PM ET)
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2024
ACCESSWIRE (Tue, 30-Apr 4:06 PM ET)
Amphastar Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
ACCESSWIRE (Mon, 1-Apr 6:02 AM ET)
Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference
ACCESSWIRE (Wed, 6-Mar 4:06 PM ET)
ACCESSWIRE (Wed, 28-Feb 4:22 PM ET)
Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
Amphastar Pharmaceuticals trades on the NASDAQ stock market under the symbol AMPH.
As of May 13, 2024, AMPH stock price climbed to $42.37 with 339,684 million shares trading.
AMPH has a beta of 0.94, meaning it tends to be less sensitive to market movements. AMPH has a correlation of 0.07 to the broad based SPY ETF.
AMPH has a market cap of $2.07 billion. This is considered a Mid Cap stock.
Last quarter Amphastar Pharmaceuticals reported $172 million in Revenue and $1.04 earnings per share. This fell short of revenue expectation by $-3 million and exceeded earnings estimates by $.30.
In the last 3 years, AMPH stock traded as high as $67.66 and as low as $17.56.
The top ETF exchange traded funds that AMPH belongs to (by Net Assets): IJR, VTI, IWM, VXF, AVUV.
AMPH has underperformed the market in the last year with a price return of +1.8% while the SPY ETF gained +28.2%. AMPH has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -22.6% and +0.8%, respectively, while the SPY returned +5.8% and +2.1%, respectively.
AMPH support price is $41.33 and resistance is $43.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AMPH stock will trade within this expected range on the day.